REVIEW
The use of biologic therapies for the management of pediatric asthma
Stephanie Lovinsky-Desir MD, MS,
Corresponding Author
Stephanie Lovinsky-Desir MD, MS
Division of Pediatric Pulmonology, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York
Correspondence Stephanie Lovinsky-Desir, MD, MS, Division of Pediatric Pulmonology, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 3959 Broadway, CHC 7-701, New York, NY 10032.
Email: [email protected]
Search for more papers by this authorStephanie Lovinsky-Desir MD, MS,
Corresponding Author
Stephanie Lovinsky-Desir MD, MS
Division of Pediatric Pulmonology, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York
Correspondence Stephanie Lovinsky-Desir, MD, MS, Division of Pediatric Pulmonology, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 3959 Broadway, CHC 7-701, New York, NY 10032.
Email: [email protected]
Search for more papers by this authorAbstract
With better understanding of the role of type 2 inflammation in allergic asthma, there has been progress made in the development of new biologic therapies targeting these specific pathways. This review will consider diagnostic criteria for using biologic therapies for pediatric asthma with special emphasis on populations that are likely to benefit the most from particular therapies. With the exception of the anti-immunoglobulin E, omalizumab, very few studies have been published on the efficacy and safety of biologic therapies in children, particularly anti-interleukin-5 (IL5) and anti-IL4/IL13 therapies. The review will highlight the scarcity of published data in pediatric-specific populations. In addition, we will consider the cost-effectiveness as well as potential long-term consequences of biologic therapies in pediatric asthma.
REFERENCES
- 1Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 5: 716-725.
- 2Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014; 6: 645-648.
- 3Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015; 1: 57-65.
- 4Locksley RM. Asthma and allergic inflammation. Cell. 2010; 6: 777-783.
- 5Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008; 3: 218-230.
- 6Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease a meta-analysis. Circulation. 2011; 7: 789-U84.
- 7Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 2:E36-e36.
- 8Lemanske RF Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002; 5:e55.
- 9Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003; 2: 182-188.
- 10Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004; 4: e308-e312.
- 11Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009; 6: 1210-1216.
- 12Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010; 6: 1285-1293.
- 13Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011; 11: 1005-1015.
- 14Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015; 6: 1476-1485.
- 15Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012; 7: 604-609.
- 16Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013; 5: 1224-1233.
- 17Rivas I, Viana M, Moreno T, et al. Child exposure to indoor and outdoor air pollutants in schools in Barcelona, Spain. Environ Int. 2014; 69: 200-212.
- 18Chung MK, Lao TT, Ting YH, Wong TW, Leung TY. Seasonality of fetal trisomy 21–have ambient air pollutants played a role? J Matern Fetal Neonatal Med. 2015; 5: 552-557.
- 19Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 7: 549-556.
- 20Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 9842: 651-659.
- 21Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 13: 1189-1197.
- 22Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 10056: 2115-2127.
- 23FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 10056: 2128-2141.
- 24Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018; 52: 4.
- 25Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 26: 2486-2496.
- 26Chung MK, Lao TT, Ting YH, Wong TW, Leung TY. Seasonality of fetal trisomy 21-have ambient air pollutants played a role? J Matern-Fetal Neo M. 2015; 5: 552-557.
- 27James P, Jankowska M, Marx C, et al. "Spatial Energetics" integrating data from GPS, accelerometry, and GIS to address obesity and inactivity. Am J Prev Med. 2016; 5: 792-800.
- 28Anderson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? Ann Allergy Asthma Immunol. 2019; 4: 367-372.
- 29Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007; 2: 149-153.
- 30Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008; 6: 670-684.
- 31Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immun. 2007; 5: 1146-1152.
- 32Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immun. 2004; 2: 265-269.
- 33Ross Z, Ito K, Johnson S, et al. Spatial and temporal estimation of air pollutants in New York City: exposure assignment for use in a birth outcomes study. Environ Health-Glob. 2013; 12: 51.
- 34Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018; 5: 1735.e9-1743.e9.
- 35 Genentec. Omalizumab (xolair) [package insert]. website. https://www.gene.com/download/pdf/xolair_prescribing.pdf. Revised May 2019. Accessed November 6, 2019.
- 36GlaksoSmithKline LLC Mepolizumab (nucala) [package insert]. website. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF. Revised September 2019. Accessed November 6, 2019.
- 37 Regereron Pharmaceuticals, Inc. Dupilumab (dupixent). website. https://www.regeneron.com/sites/default/files/Dupixent_FPI.pdf. Revised June 2019. Accessed November 6, 2019.
- 38AstraZeneca Pharmaceuticals LP Benralizumab (fasenra) [package insert]. website. https://www.azpicentral.com/fasenra/fasenra.pdf#page=1. Revised October 2019. Accessed November 6, 2019.
- 39Lieberman PL, Jones I, Rajwanshi R, Rosen K, Umetsu DT. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics. J Allergy Clin Immunol. 2017; 6: 1734.e4-1736.e4.
- 40Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014; 3: 560.e4-567.e4.
Citing Literature
